This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXNPEK2I06R_L.jpg
(Reuters) – AstraZeneca (NASDAQ:AZN) said on Tuesday it has agreed to buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash.
The drugmaker will pay $21 per Fusion share plus a non-transferable contingent value right of $3 per share.
